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Abstract
Background: A high neutrophil-to-lymphocyte ratio (NLR) is a marker of systemic inflammation and together with
the platelet-to-lymphocyte ratio (PLR) is associated with worse outcomes in several solid tumors. We investigated
the prognostic value of NLR and PLR in patients with head and neck squamous cell carcinoma (HNSCC) treated
with primary or adjuvant (chemo)radiotherapy ((C)RT).
Methods: A retrospective chart review of consecutive patients with HNSCC was performed. Neutrophil-to-
lymphocyte ratio and PLR were computed using complete blood counts (CBCs) performed within 10 days before
treatment start. The prognostic role of NLR and PLR was evaluated with univariable and multivariable Cox
regression analyses adjusting for disease-specific prognostic factors. NLR and PLR were assessed as log-transformed
continuous variables (log NLR and log PLR). Endpoints of interest were overall survival (OS), locoregional recurrence-
free survival (LRFS), distant recurrence-free survival (DRFS), and acute toxicity.
Results: We analyzed 186 patients treated from 2007 to 2010. Primary sites were oropharynx (45%), oral cavity
(28%), hypopharynx (14%), and larynx (13%). Median follow-up was 49 months. Higher NLR was associated with OS
(adjusted HR per 1 unit higher log NLR = 1.81 (1.16–2.81), p = 0.012), whereas no association could be shown with
LRFS (HR = 1.49 (0,83-2,68), p = 0.182), DRFS (HR = 1.38 (0.65–3.22), p = 0.4), or acute toxicity grade ≥ 2. PLR was not
associated with outcome, nor with toxicity.
Conclusion: Our data suggest that in HNSCC patients treated with primary or adjuvant (C)RT, NLR is an independent
predictor of mortality, but not disease-specific outcomes or toxicity. Neutrophil-to-lymphocyte ratio is a readily available
biomarker that could improve pre-treatment prognostication and may be used for risk-stratification.
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Background
Risk stratification of patients diagnosed with head and
neck squamous cell carcinoma (HNSCC) poses an
important challenge [1]. Currently, some of the widely
used factors are smoking and human papillomavirus
(HPV) status, age, performance status, and tumor stage.
Nomograms based on baseline characteristics can
enhance prognostic prediction [2].
Inflammation is a hallmark of cancer [3], which is
shown to play an important role in tumor development
and progression [4–6]. An elevation of circulating neu-
trophil count is thought to be the result of tumor cells
releasing cytokines, which stimulate the bone marrow to
produce neutrophils [7–9]. Cytokines released by neu-
trophils also promote angiogenesis leading to tumor
growth and metastasis [10–15]. There is an increasing
interest in the use of hematological parameters as prog-
nostic factors in malignancies. Neutrophil, lymphocyte,
and platelet counts, either as individual values or in rela-
tion to each other, could be associated with the cancer
prognosis [16, 17]. The neutrophil-to-lymphocyte ratio
(NLR) is an emerging marker of host inflammation,
which reflects the relation between circulating neutro-
phil and lymphocyte counts. It can be easily calculated
from routine complete blood counts (CBCs) with differ-
entiation. The independent prognostic value of NLR has
been shown for a variety of solid malignancies [17–20].
In addition to NLR, the platelet-to-lymphocyte ratio
(PLR) has also been shown to be a potential prognostic
factor [2, 19]. Several studies involving HNSCC have
shown an association between inflammation and worse
prognosis [21–27]. However, information about the
possible value of pretreatment NLR or PLR on toxicity is
limited [18–29].
In this study, we retrospectively evaluated the prog-
nostic impact of pretreatment NLR and PLR on onco-
logical outcomes and toxicity in HNSCC patients treated
with primary or adjuvant curative-intended (chemo-)
radiotherapy ((C)RT). We hypothesized that elevated
NLR and/or PLR are associated with detrimental
survival; we also explored NRL and PLR associations
with acute treatment-related toxicity since it has
prognostic value in primary and adjuvant (C)RT for
HNSCC [30, 31].
Methods
Patient selection
Medical records of HNSCC patients consecutively
treated with primary or adjuvant curative-intent
intensity-modulated radiation therapy with or without
concomitant systemic therapy between January 2007 and
December 2010 at the Department of Radiation
Oncology, Inselspital, Bern University Hospital were
retrospectively analyzed. Patients diagnosed with oral
cavity (OCC), oropharynx (OC), hypopharynx (HC) and
laryngeal cancers (LC) were included in the analysis.
History of another malignancy within 5 years of diagno-
sis, prior radiation to the head and neck, non-squamous
cell carcinoma histology, distant metastases, lack of dif-
ferentiated CBC within 10 days before oncologic surgery
or RT start, and early abortion of RT were defined as
exclusion criteria. This study was approved by the local
ethics committee (289/2014).
Treatment and follow-up
The standard treatment was based on institutional
policies following the multidisciplinary tumor board
decision as previously published [32, 33]. All cases were
presented at the weekly institutional interdisciplinary
head-and-neck tumor board. After completion of staging
examinations and final TNM staging (AJCC), selection
of treatment modalities and treatment sequencing were
defined. The standard treatment in OCC was to perform
surgery followed by adjuvant radiotherapy (RT) [30, 32],
while in OC, HC and LC the joint recommendations of
the multidisciplinary meeting was primary RT [31, 33].
Case-based decisions were made concerning the use of
concomitant systemic therapy and up-front neck dissec-
tion. The delivery of radiotherapy, the definition of
clinical target volume (CTV) and planned target volume
(PTV) followed departmental guidelines [32, 33] based
on international recommendations [34–36]. All treat-
ment plans were contoured and calculated using Eclipse
treatment planning system (Varian Medical Systems,
Palo Alto, CA). The standard concomitant therapy
consisted of cisplatin 100 mg/m2 day 1 in three-week in-
tervals for all patients. In few cases of induction chemo-
therapy, cisplatin, docetaxel, and 5-fluorouracil were
used. Patients not deemed medically fit for cisplatin
chemotherapy because of pre-existing co-morbidities
were evaluated for weekly treatment with monoclonal
antibody cetuximab [37] or carboplatin three weekly.
Pre-treatment CBC with differential values was used to
calculate NLR and PLR.
Potential causes of changes in the CBC (e.g. infec-
tion, steroid use) were identified, and patients were
excluded from the analysis. Patients were regularly
followed, and toxicities were graded according to the
National Cancer Institute (NCI) Common Terminology
Criteria for Adverse Events (CTCAE) version 4.03
(https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/
CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf).
Statistical analysis
NLR was calculated by dividing absolute neutrophil
count by absolute lymphocyte count measured in per-
ipheral blood. PLR was calculated by dividing absolute
thrombocyte count by absolute lymphocyte count. Due
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to its non-normal distribution, NLR and PLR were loge--
transformed to obtain symmetric distributions and then
analyzed as continuous variables. Frequencies and
percentages are reported for categorical variables,
medians with range or interquartile range for continuous
variables. The primary endpoint of the study was overall
survival (OS), and the secondary endpoints were
locoregional relapse-free survival (LRFS) and distant
recurrence-free survival (DRFS). Time-to-event was
calculated for OS, LRFS, and DRFS from the start of RT
to death (OS), locoregional relapse (LRFS), and distant
recurrence (DRFS), respectively, with censoring of
patients without such events at last follow up. Median
times to event were estimated using the Kaplan Meier
method. The prognostic value of NLR and PLR, and
other variables (i.e. age, gender, smoking status,
Karnofsky Performance Status (KPS), UICC stage, tumor
grade, hemoglobin level) were assessed by univariable
Cox regression analysis. Subsequently, multivariable
analysis with forward elimination was planned with
inclusion of all variables with a p-value < 0.05 in the
univariable analysis. The association of NLR and PLR
with acute and late toxicities (i.e. pain, dermatitis, muco-
sitis, dysphagia, xerostomia) was examined using logistic
regression. Analyses were carried out using SPSS version
23 (IBM Corp., Chicago, IL). The threshold for statistical
significance was set at p < 0.05, and no correction for
multiple testing was performed.
Results
Patients
One hundred and eighty-six patients were included in
the study. Patients’ and disease characteristics are pre-
sented in Table 1. The majority of patients were male
and in good performance status (KPS ≥ 70). The primary
Table 1 Patients’ and disease characteristics
Age
median (range), years 61 (41–88)
≤ 60, N (%) 86 (46)
> 60 to ≤70, N (%) 64 (34)
> 70 to ≤80, N (%) 27 (15)
> 80, N (%) 9 (5)
Gender, N (%)
female 40 (22)
male 146 (79)
Smoking status
never smoker 17 (6)
previous smoker 33 (31)
current smoker 58 (54)
missing 108
High risk alcohol consumption
No 49 (46)
Yes 54 (51)
in the past 4 (4)
missing 79
Karnofsky Performance Status
median (range) 90 (50–100)
> 70, N (%) 160 (86)
≤ 70, N (%) 26 (14)
Oncological resection of primary tumor
yes 56 (30)
no 130 (70)
Induction chemotherapy
yes 15 (8)
no 171 (92
Concomitant systemic therapy
no 38 (20)
cisplatin or carboplatin 125 (67)
cetuximab 23 (12)
Site of primary tumor, N (%)
oral cavity 52 (28)
oropharynx 83 (45)
hypopharynx 27 (15)
larynx 24 (13)
UICC stage, N (%)
I 5 (3)
II 11 (6)
III 44 (24)
IV 126 (68)
Table 1 Patients’ and disease characteristics (Continued)
Tumor grade, N (%)
G1 1 (1)
G2 113 (61)
G3 72 (39)
Hemoglobin (g/dL)
median (IQR) 13.3 (12.0–14.4)
missing 12
Neutrophil-to-lymphocyte ratio
median (IQR) 3.28 (2.15–4.70)
missing 20
Platelet-to-lymphocyte ratio
median (IQR) 189 (136–254)
missing 20
IQR inter-quartile range, UICC Union for International Cancer Control
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tumor was located in the oral cavity or oropharynx in
approximately 75% of the cases, and more than half of
all patients had UICC stage IVA or IVB disease. Median
NLR and PLR were 3.28 and 189, respectively. There
was a statistically significant correlation between NLR
and PLR (Spearman’s rho = 0.65, p < 0.001). Baseline
NLR and PLR were not associated with gender, smoking
status, site of the primary tumor, stage of disease or
tumor grade.
Overall survival
At a median follow-up time of 40 months, 60 patients
(32%) died; median OS was not reached. Higher NLR
was associated with lower OS (Table 2). When dividing
the population into two groups according to the median
NLR, there was a significant OS difference between the
groups (Fig. 1). For PLR there was a non-significant
association between higher PLR and lower OS (Fig. 2).
On univariable analysis loge NLR was associated with
OS. Also, older age, worse Karnofsky Performance Status
(KPS ≤ 70), and UICC stage IV were associated with
lower OS. Performance status, UICC stage IV and loge
NLR remained of prognostic value in multivariable
analysis (Table 2).
Recurrence
Of the variables tested, only UICC stage IV was associ-
ated with increased loco-regional, distant, and any recur-
rence rate, whereas no association was found for all
other variables tested (Table 3). Consequently, no multi-
variable analyses were conducted. In patients with high
NLR, recurrences occurred earlier, but the correlation
was not statistically significant (Fig. 3).
Toxicity
Rates and grades of the most common acute toxicities
are summarized in Table 4. There was no correlation
between baseline NLR or PLR and the grade of toxicity
(data not shown).
Discussion
NLR is the object of numerous previously published
studies. Not only in oncology but also in other
disciplines, blood counts reflecting the complexity of the
immune system can be easily obtained at low costs,
which may impact daily clinical practice. About 15–20%
of all cancer deaths worldwide seem to be associated
with underlying infections and inflammatory reactions
[38]. Many triggers of chronic inflammation increase the
risk of developing cancer. These triggers, for example,
include microbial infections such as Helicobacter pyl-
ori (associated with stomach cancer), inflammatory
bowel disease (associated with bowel cancer) and
prostatitis (associated with prostate cancer) [38]. Des-
pite conflicting studies, treatment with non-steroidal
anti-inflammatory agents has been associated with
reduced cancer incidence and mortality [38–41].
Increased NLR is associated with poorer outcomes in
many solid tumors, be it early or advanced stage can-
cer [17]. An early decrease in NLR may be associated
with more favorable outcomes and higher response
rates [42], whereas an increase in NLR in the first
weeks of treatment had the opposite effect [42].
In this study with a relatively large cohort of HNSCC
patients treated with (C)RT with curative intention, an
elevated NLR at baseline was associated with a shorter
OS but not with disease recurrence or toxicities. Our
findings of a negative prognostic role of NLR are in
accordance with other studies [26, 43] that have investi-
gated NLR in HNSCC. In contrast to our results,
Rassouli et al. [44] have demonstrated a statistically
significant impact of PLR on OS. Worth to note, such
associations were observed at various cut-offs in different
studies. They have also shown that an increased NLR was
Table 2 Univariable and multivariable Cox regression analysis of overall survival
univariable analysis multivariable analysis
HR (95% CI) P HR (95% CI) P
Age per 10 years older 1.32 (1.03–1.69) 0.026*
Gender male (vs. female) 1.17 (0.61–2.25) 0.639
Smoking status never smoker (vs. current/past) 0.66 (0.20–2.19) 0.492
Karnofsky Performance Status per 10 higher 0.76 (0.62–0.92) 0.005* 0.76 (0.62–0.98) 0.030*
UICC stage IVA-B (vs. I-III) 1.87 (1.01–3.47) 0.045*
Tumor grade G3 (vs. G1-G2) 0.91 (0.54–1.54) 0.731
Hemoglobin per 1 g/dL higher 0.89 (0.77–1.04) 0.143
log NLR per 1 log NLR higher 1.81 (1.16–2.81) 0.009* 1.58 (1.01–2.47) 0.043*
log PLR per 1 log PLR higher 1.62 (0.99–2.63) 0.054
CI confidence interval, G tumor grade, HR hazard ratio, log NLR natural logarithm of neutrophil-to-lymphocyte ratio, log PLR natural logarithm of platelet-to-
lymphocyte ratio, UICC Union for International Cancer Control; *statistically significant
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Fig. 1 Overall survival of NLR higher than median vs. equal or lower than median
Fig. 2 Overall survival of PLR higher than median vs. equal or lower than median
Bojaxhiu et al. Radiation Oncology          (2018) 13:216 Page 5 of 9
not only associated with decreased OS but with higher
recurrence rates too [44]; which was not shown in our
cohort and another study from the United Kingdom [45].
Along with the increased NLR in malignant disease, a
possible explanation for a lower OS could also be a
cause of death not attributable to cancer, but other
co-morbidities such as a cardiac cause where it could
also be shown that an increased NLR is predictive for
cardiac mortality [46]. It is also known that smokers
have a “smoker’s leukocytosis” [37, 38, 47, 48]. In our co-
hort, most patients are at least ex-smokers (80%), and at
least one third continued smoking during and after
radiation. Therefore, it is possible that the patients with
a smoker’s leukocytosis have died earlier from
smoking-related comorbidities [49].
Several limitations to our study should be considered.
First, this was a retrospective analysis with possible
selection bias and confounding variables. We included
16 patients (9%) with early-stage disease and 15 (8%)
patients who had neoadjuvant chemotherapy, which may
have introduced some heterogeneity to our cohort.
Second, we were unable to capture data on HPV status
systematically. Studies have shown an important inter-
action between HPV status, immunomodulation and
Table 3 Univariable Cox regression analysis of recurrence
Univariable analysis
HR (95% CI) P
Loco-regional recurrence (38 events)
Age per 10 years older 1.08 (0.80–1.48) 0.607
Gender male vs. female 1.21 (0.53–2.75) 0.648
Smoking status never smoker (vs. current/past) 1.68 (0.34–8.31) 0.526
Karnofsky Performance Status KPS over 70 0.55 (0.23–1.35) 0.191
UICC stage IVA-B (vs. I-III) 3.43 (1.34–8.78) 0.010*
Tumor grade G3 (vs. G1-G2) 0.78 (0.40–1.53) 0.477
Hemoglobin per 1 g/dL higher 0.92 (0.76–1.13) 0.424
log NLR per 1 log NLR higher 1.49 (0.83–2.68) 0.182
log PLR per 1 log PLR higher 1.65 (0.88–3.10) 0.117
Distant recurrence (20 events)
Age per 10 years older 0.77 (0.49–1.22) 0.272
Gender male 2.48 (0.57–10.7) 0.224
Smoking status never smoker (vs. current/past) 0.04 (0.00–22.86) 0.314
Karnofsky Performance Status KPS over 70 2.53 (0.34–18.94) 0.367
UICC stage IV (vs. I-III) 9.91 (1.33–74.03) 0.025*
Tumor grade G3 (vs. lower) 1.53 (0.64–3.68) 0.342
Hemoglobin per 1 g/dL higher 1.11 (0.84–1.46) 0.472
log NLR per 1 log NLR higher 1.38 (0.65–2.91) 0.400
log PLR per 1 log PLR higher 1.44 (0.65–3.22) 0.371
Any recurrence (46 events)
Age per 10 years older 1.04 (0.78–1.28) 0.779
Gender male 1.30 (0.61–2.79) 0.501
Smoking status never smoker (vs. current/past) 0.60 (014–2.63) 0.501
Karnofsky Performance Status KPS over 70 0.74 (0.33–1.65) 0.457
Localization larynx or hypopharynx (vs. other) 1.24 (0.66–2.33) 0.497
UICC stage IV (vs. I-III) 3.49 (1.48–8.24) 0.004*
Tumor grade G3 (vs. G1-G2) 0.96 (0.53–1.74) 0.891
Hemoglobin per 1 g/dL higher 0.95 (0.79–1.14) 0.948
log NLR per 1 log NLR higher 1.49 (0.88–2.53) 0.134
log PLR per 1 log PLR higher 1.55 (0.88–2.74) 0.128
CI confidence interval, G tumor grade, HR hazard ratio, log NLR natural logarithm of neutrophil-to-lymphocyte ratio, log PLR natural logarithm of platelet-to-
lymphocyte ratio, UICC Union for International Cancer Control; *statistically significant
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clinical outcome [50]. Therefore, there might be differ-
ent results in HPV-associated and unassociated tumors
[51]. Since this is a retrospective study, there might be
unknown causes of CBC changes that have not been
identified. Beside patient and tumor-specific factors
which may influence the complex cascades of the im-
mune system, it must also be noted that despite clinical
benefit, the dichotomization or grouping of continuous
variables in statistical analysis is accompanied by a loss
of the statistical power. To account for this, NLR and
PLR were analyzed as (log-transformed) continuous
variables. Lastly, an overestimation of statistical signifi-
cance due to multiple testing is possible. Although these
results should be validated in other cohorts, we repro-
duced some of the previously reported studies [26, 43]
on the interface of systemic inflammatory pathways and
OS. Therefore, we provide data on surrogate values for
inflammation as predictors of clinical outcomes;
however, a causal relationship and its impact on tumor
aggressiveness or tumor microenvironment warrants
further investigation.
Conclusion
Our data suggest that in HNSCC patients treated with
primary or adjuvant (C)RT, NLR is an independent
predictor of OS. NLR is a readily available biomarker
that could improve pre-treatment risk stratification.
Abbreviations
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PLR: Platelet-to-lymphocyte ratio; RT: Radiotherapy; UICC: Union for
International Cancer Control
Fig. 3 Recurrence-free survival of NLR higher than median vs. equal or lower than median
Table 4 Selected toxicities of 183 patients (toxicities of 3
patients missing)
G1 G2 G3 G4
Symptoms prior to radiotherapy
Pain 52 (28) 30 (16) 2 (1) 0
Dysphagia 52 (28) 32 (17) 11 (6) 0
Acute toxicities
Pain 42 (23) 91 (49) 45 (24) 1 (1)
Dermatitis 44 (24) 117 (63) 22 (12) 0
Mucositis 31 (17) 110 (59) 40 (22) 0
Dysphagia 23 (12) 80 (43) 70 (38) 1 (1)
Xerostomia 63 (34) 8 (4) 0 0
Grades according to Common Terminology Criteria for Adverse Events
(CTCAE) v4.03
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